RESEARCH TRIANGLE PARK - Five years after launching with a team headlined by local life sciences "rainmaker" Steve Butts and $49 million in capital, Arrivo
Five years after launching with a team headlined by local life sciences “rainmaker” Steve Butts and $49 million in capital, Morrisville-based Arrivo BioVentures is emerging from stealth mode with four drugs in its pipeline.
3 Value Stocks That ll Make You Richer in the Second Half of 2021 (and Beyond) fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Author Bio
Eric has been writing about stocks and finance since the mid-1990s, when he lived in Prague, Czech Republic. Over the course of a varied career, he has also been a radio newscaster, an investment banker, and a bass player in a selection of rock and roll bands. A native New Yorker, he currently lives in Los Angeles.
GW Pharmaceuticals (NASDAQ:GWPH) has released what is very possibly its final earnings report as an independent company.
On Tuesday, the maker of drugs derived from cannabis published its fourth-quarter results, which revealed that it earned $148 million in revenue for the period. That was nearly 36% higher on a year-over-year basis. But its net loss deepened across that stretch of time, to just over $29 million ($0.08 per share) from the fourth-quarter 2019 deficit of nearly $25 million.